エマージェンシー・ケア　別冊　救急医療　達人に学ぶ!　Vol.1

出版社： メディカ出版
発行日： 2013-10-21
分野： 臨床医学：一般  >  雑誌
ISSN： 13496557
雑誌名：
特集： 救急医療　達人に学ぶ！　Vol.1
電子書籍版： 2014-04-01 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,090 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,090 円(税込)

購入する

目次

  • エマージェンシー・ケア　別冊　救急医療　達人に学ぶ！　Vol.1

    ―目次―

    特集　救急医療　達人に学ぶ！　Vol.1

    ＜1＞トラネキサム酸：日本から世界へ
    ＜2＞敗血症性多臓器不全に対する治療戦略
    ＜3＞東京DMAT
    ＜4＞SIRS関連凝固異常（SAC）という新たな概念：
    　　　その早期診断と治療
    ＜5＞Surviving Sepsis Campaign Guideline（SSCG）により
    　　　敗血症の救命率は向上したか？
    ＜6＞災害拠点病院である大学病院としての災害時におけ
    　　　医療展開とそのコンセプト
    ＜7＞救急医療：効率的に手技を遂行するために必要なこと
    ＜8＞東日本大震災における医療支援を教訓とした東京都の
    　　　新たな災害医療体制について
    ＜9＞災害医療の取り組み：
    　　　病院対応からDMAT，広域緊急搬送システムへ

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[1] トラネキサム酸 : 日本から世界へ

P.14 掲載の参考文献
1) Kobe research project on thrombosis and haemostasis. Strategy for creating new medicine by Shosuke Okamoto 2003.
 
2) Okamoto, S. et al. Amino-methyl-cyclohexane-carbolic acid : AMCHA. A new potent inhibitor of fibrinolysis. Keio J Med. 11, 1962, 105-15.
 
3) Henry, DA. et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 4, 2007, CD001886.
PubMed
4) Ker, K. et al. Effect of tranexamic acid on surgical bleeding : systematic review and cumulative meta-analysis. BMJ. 344, 2012, e3054. Epub 2012/05/23.
 
5) The CRASH-2 Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) : a randomised, placebo-controlled trial. Lancet. 376, 2010, 23-32.
 
6) The CRASH-2 collaborators. Importance of early treatment with tranexamic acid in bleeding trauma patients : exploratory analysis of the CRASH-2 trial. Lancet. 377, 2011, 1096-101.
PubMed
7) Guerriero, C. et al. Cost-Effectiveness Analysis of Administering Tranexamic Acid to Bleeding Trauma Patients Using Evidence from the CRASH-2 Trial. PLoS ONE. 6 (5), 2011, e18987. doi : 10.1371/journal.pone.0018987.
 
8) Morrison, JJ. et al. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg. 147, 2012, 113-9.
PubMed
9) Ker, K. et al. Avoidable mortality from giving tranexamic acid to bleeding trauma patients : an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emerg Med. 12, 2012, 3. Epub 2012/03/03.
 
10) Shakur, H. et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial) : tranexamic acid for the treatment of postpartum haemorrhage : an international randomised, double blind placebo controlled trial. Trials. 11, 2010, 40.
PubMed

[2] 敗血症性多臓器不全に対する治療戦略

P.31 掲載の参考文献
1) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 20, 1992, 864-74.
PubMed
2) Finfer, S. et al. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 30, 2004, 580-8.
 
3) Vincent, JL. et al. Sepsis in European intensive care units : Results of SOAP study. Crit care Med. 34, 2006, 344-53.
PubMed
4) 松田直之ほか. 日本版重症敗血症診断・治療ガイドライン作成に向けて (Sepsis Registry委員会報告). 日集中医誌. 18, Suppl. 2011, 194.
 
5) 日本集中治療医学会Sepsis Registry委員会. 日本版敗血症診療ガイドラインThe Japanese Guidelines for the Management of Sepsis. 日集中医誌. 20, 2013, 124-73.
 
6) Dellinger, RP. et al. Surviving Sepsis Campaign : International Guidelines for Management of Severe Sepsis and Septic Shock : 2012. Crit Care Med. 41, 2013, 580-637.
PubMed
7) Dellinger, RP. et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 32, 2004, 858-73.
PubMed
8) R. Phillip Dellinger, et al. Surviving Sepsis Campaign : International guidelines for management of severe sepsis and septic shock : 2008. Intensive Care Med. 34, 2008, 17-60.
PubMed
9) GRADE working group. Grading quality of evidence and strength of recommendations. BMJ. 328, 2004, 1490-8.
 
10) Bouza, E. et al. Is the Volume of Blood Cultured Still a Significant Factor in the Diagnosis of Bloodstream Infections? Journal of Clinical Microbiology. 45, 2007, 2765-9.
 
11) BLOT, F. et al. Earlier Positivity of Central-Venous-versus Peripheral-Blood Cultures Is Highly Predictive of Catheter-Related Sepsis. J Clin Microbiol. 36, 1998, 105-9.
PubMed
12) Evangelos, J. et al. Should Procalcitonin be Introduced in the Diagnostic Criteria for the Systemic Inflammatory Response Syndrome and Sepsis?. Journal of Critical Care. 19, 2004, 152-7.
 
13) Meisner, M. Procalcitonin : Biochemistry and Clinical Diagnosis. 1st.ed. Germany, Uni-Med Verlag Ag. 2010, 20.
 
14) Schuetz, P. et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections : The ProHOSP Randomized Controlled Trial. JAMA. 302, 2009, 1059-66.
PubMed
15) Cuquemelle, E. et al. Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study. Intensive Care Med. 37, 2011, 796-800.
PubMed
16) Kumar, A. et al. Rapidity of source control implementation following onset of hypotension is a major determinant of survival in human septic shock : 564. Crit Care Med. 32 (12 Suppl), 2004, A158.
 
17) Bakker, J. et al. Don't take vitals, take a lactate. Intensive care Med. 33, 2007, 1863-65.
 
18) Rivers, E. et al. Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock. N Engl J Med. 345, 2001, 1368-77.
PubMed
19) Kortgen, A. et al. Implementation of an evidence-based "standard operating procedure" and outcome in septic shock. Crit Care Med. 34, 2006, 943-9.
PubMed
20) Scott, T. et al. Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med. 34, 2006, 2707-13.
 
21) 一般社団法人日本集中治療医学会. "敗血症/敗血症性ショック". 集中治療専門医テキスト (電子版). 東京, 総合医学社, 2013, 481.
 
22) LeDoux, D. et al. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med. 28, 2000, 2729-32.
PubMed
23) Alan, E. et al. Cost-effectiveness of an emergency department-based early sepsis resuscitation protocol. Crit Care Med. 39, 2011, 1306-12.
 
24) The SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 350, 2004, 2247-56.
 
25) Schierhout, G. et al. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients : a systematic review of randomized trials. BMJ. 316, 1998, 961-4.
 
26) Choi, PT. et al. Crystalloids vs. colloids in fluid resuscitation : A systematic review. Crit Care Med. 27, 1999, 200-10.
PubMed
27) Sakr, Y. et al. Effects of hydroxyethyl starch administration on renal function in critically ill patients. British Journal of Anaesthesia. 98, 2007, 216-24.
PubMed
28) Russell, JA. et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med. 37, 2009, 811-8.
PubMed
29) Russell, JA. et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 358, 2008, 877-87.
PubMed
30) Martin, W. et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock : Incidence and risk factors. Crit Care Med. 31, 2003, 1394-8.
 
31) Ibrahim, EH. et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 118, 2000, 146-55.
PubMed
32) 日本血栓止血学会学術標準化委員会. 科学的根拠に基づいた感染症に伴なうDIC治療のエキスパートコンセンサス. 血栓止血誌. 20, 2009, 77-113.
 
33) Levi, M. et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 145, 2009, 24-33.
PubMed
34) 丸藤哲ほか. 急性期DIC診断基準. 多施設前向き検討結果報告. 日救急医会誌. 16, 2005, 188-202.
 
35) Taylor, FB. Jr. et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation? On behalf of the Scientific Subcommittee on International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost. 86, 2001, 1372-30.
 
36) Warren, BL. et al. KyberSept Trial Study Group : Caring for the critically ill patient. High-dose antithrombin III in severe sepsis : a randomized controlled trial. JAMA. 286, 2001, 1869-78.
 
37) Mathieu, D. et al. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis : a prospective, controlled clinical study. Crit Care Med. 19, 1991, 1352-6.
 
38) Cooper, DJ. et al. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med. 112, 1990, 492-8.
 
39) Uchino, S. et al. Beginning and Ending Supportive Therapy for the Kidney (BEST kidney) Investigators. Acute renal multicenter study. JAMA. 294, 2005, 813-8.
PubMed
40) Bagshaw, SM. et al. Early acute kidney injury and sepsis : a multicentre evaluation. Crit Care. 12 (2), 2008, R47, Epub.
 
41) Hoste, EA. et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients : a cohort analysis. Crit Care. 10 (3), 2006, R73.
PubMed
42) Karvellas, CJ. et al. A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury : a systematic review and meta-analysis. Crit Care. 15 (1), 2011, R72.
PubMed
43) The RENAL Replacement Therapy Study Investigators : Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients. N Engl J Med. 361, 2009, 1627-38.
 
44) Vesconi, S. et al. Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Crit Care. 13, 2009, R57.
PubMed
45) Cruz, DN. et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis : a systematic review. Crit Care. 11, 2007, R47.
PubMed
46) Cruz, DN. et al. Polymyxin-B hemoperfusion and endotoxin removal : lessons from a review of the literature. Contrib Nephrol. 167, 2010, 77-82.
PubMed
47) Vincent, JL. et al. A pilot-controlled study of polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock. 23, 2005, 400-5.
PubMed
48) Cruz, DN. et al. Early use of polymyxin B hemoperfusion in abdominal septic shock : the EUPHAS randomized controlled trial. JAMA. 17, 2009, 2445-52.
 
49) 清水智治ほか. 下部消化管穿孔術後に対するPMX治療の有用性に関する検討. 日本外科感染症学会雑誌. 4, 2007, 189-95.
 
50) Rachoin, JS. et al. Endotoxin removal : how far from the evidence? From EUPHAS to EUPHRATES. Contrib Nephrol. 167, 2010, 111-8.
PubMed
51) Takeda, S. et al. Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intensive Care Med. 36, 2010, 906-7.
PubMed
52) McClave, SA. et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patients : Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN). J Parenter Enteral Nutr. 33, 2009, 277-316.
 
53) Marik, PE. et al. Early enteral nutrition in acutely ill patients : a systematic review. Crit Care Med. 29, 2001, 2264-70.
PubMed
54) Elke, G. et al. Current practice in nutritional support and its association with mortality in septic patients--results from a national, prospective, multicenter study. Crit Care Med. 36, 2008, 1762-7.
PubMed
55) Casaer, MP. et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 365, 2011, 506-17.
PubMed
56) Pontes-Arruda, A. et al. Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis : results from a multicenter, prospective, randomized, double-blinded, controlled study : the INTERSEPT study. Crit Care. 15 (3), 2011, R144.
 

[3] 東京DMAT

P.46 掲載の参考文献
1) 災害医療派遣チーム (「東京DMAT」) 運営要綱 : 平成16年7月22日付16健医救第276号.
 
2) 東京消防庁東京DMAT連携隊の運用等に関する要綱 : 平成19年3月2日付18救管第509号.
 
3) 東京DMAT運営協議会設置要綱 : 平成20年5月7日19福保医救第884号.
 

[4] SIRS関連凝固異常 ( SAC ) という新たな概念 : その早期診断と治療

P.58 掲載の参考文献
1) Bone, RC. et al. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Amerian college of Chest Physicians/Society of Critical Care Medicine. Chest. 10, 1992, 1644-55.
 
2) Levi, M. et al. Inflammation and coagulation. Crit Care Med. 38, 2010, S26-S34.
PubMed
3) Okabayashi, K. et al. Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol. 76, 2004, 225-9.
 
4) 小関一英ほか. DIC早期診断基準としての "SIRS-Associated Coagulopathy (SAC)". バイオメディカル. 14, 2004, 19-24.
 
5) 丸藤哲ほか. 急性期DIC診断基準. 多施設前向き検討結果報告. 日救急医会誌. 16, 2005, 188-202.
 
6) Bernard, GR. et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 149, 1994, 818-24.
PubMed
7) Gando, S. et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : comparing current criteria. Crit Care Med. 34, 2006, 625-31.
PubMed
8) 小関 一英. "第1章 定義・概念 SIRS-Associated Coagulopathy (SAC) の概念". DIC～とびらを拓く第三世代へ～第一世代第二世代そして…培った実績を活かす第三世代. 臨床病理レビュー特集第147号. 2001, 13-9.
 
9) Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science. 5, 303, 2004, 1532-5.
 
10) Clark, SR. et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nature Medicine. 13, 2007, 463-9.
PubMed
11) Phillipson, M. et al. The neutrophil in vascular inflammation. Nat Med. 17, 2011, 1381-90.
PubMed
12) von Kockritz-Blickwede, M. et al. Innate immunity turned inside-out : antimicrobial defense by phagocyte extracellular traps. J Mol Med. 87 (8), 2009, 775-83.
PubMed
13) Martinelli, S. et al. Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation. J Biol Chem. 27942, 2004, 44123-32.
 
14) Papayannopoulos, V. et al. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 191, 2010, 677-91.
PubMed
15) Gupta, AK. et al. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosismediated cell death. FEBS Lett. 584 (14), 2010, 3193-7.
PubMed
16) Xu, J. et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 15, 2009, 1318-21.
PubMed
17) Esmon, C. Inflammation and thrombosis. J Thromb Haemost. 1, 2003, 1343-8.
PubMed
18) Ranieri, VM. et al. PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 366, 2012, 2055-64.
 
19) Li, YH. et al. The role of thrombomodulin lectin-like domain in inflammation. J Biomed Sci. 19, 2012, 34.
 
20) Shi, CS. et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood. 112, 2008, 3661-70.
PubMed
21) Abeyama, K. et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 115, 2005, 1267-74.
 
22) Ito, T. et al. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexe. Arterioscler Thromb Vasc Biol. 28, 2008, 1825-30.
PubMed
23) Conway, EM. et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med. 196, 2002, 565-77.
PubMed
24) Steven, M. et al. Antithrombin, heparin, and heparan sulfate. Crit Care Med. 30 [Suppl], 2002, S325-S331.
 
25) Hoffmann, JN. et al. Adverse effect of heparin on antithrombin action during endotoxemia : microhemodynamic and cellular mechanisms. Thromb Haemost. 88, 2002, 242-52.
PubMed
26) Warren, BL. et al. The KyberSept Trial Study Group : High-dose antithrombin III in severe sepsis. A randomized controlled trial. J Am Med Assoc. 286, 2001, 1869-78.
 
27) Kienast, J. et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 4, 2006, 90-7.
 
28) Iba, T. et al. Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model. Crit Care., 13 (6), 2009, R203. doi : 10.1186/cc8210. Epub 2009 Dec 14.
 
29) Nakahara, K. et al. Use of antithrombin and thrombomodulin in the management of disseminated intravascular coagulation in patients with acute cholangitis. Gut Liver. 7, 2013, 363-70.
PubMed

[5] Surviving Sepsis Campaign Guideline ( SSCG ) により敗血症の救命率は向上したか ?

P.72 掲載の参考文献
1) Dellinger, RP. et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 32, 2004, 858-72.
PubMed
2) Rivers, E. et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 345, 2001, 1368-77.
PubMed
3) Dellinger, RP. et al. Surviving Sepsis Campaign Guidelines for management of severe sepsis and septic shock. Crit Care Med. 36, 2008, 296-327.
PubMed
4) 織田成人. Surviving Sepsis Campaign Guideline (SSCG) の概要. 医学のあゆみ. 227, 2008, 859-64.
 
5) Dellinger, RP. et al. Surviving sepsis campaign : International guidelines for management of severe sepsis and septic shock : 2012. Crit Care Medicine. 41, 2013, 580-637.
 
6) Castellanos-Ortega, A. et al. Impact of the surviving sepsis campaign protocols on hospital length of stay and mortality in septic shock patients : results of a three-year follow-up quasi-experimental study. Crit Care Med. 38, 2010, 1036-43.
PubMed
7) Ferrer, R. et al. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. J Am Med Assoc. 299, 2008, 2294-303.
 
8) 平澤博之ほか. 持続血液濾過透析はサイトカインを除去するか : non renal indecationを目指して. 日集中医誌. 5, 1998, 345-55.
 
9) Ferrer, R. et al. Effectiveness of treatments for severe sepsis : a prospective, multicenter, observational study. Am J Respir Crit Care Med. 180, 2009, 861-6.
PubMed
10) Gao, F. et al. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis : a prospective observational study. Crit Care. 9, 2005, R764-770.
PubMed
11) Levy, MM. et al. The surviving sepsis campaign : results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 36, 2010, 222-31.
PubMed
12) Trzeciak, S. et al. Translating research to clinical practice : a 1-year experience with implementing early goal-directed therapy for septic shock in the emergency department. Chest. 129, 2006, 225-32.
PubMed
13) Varpula, M. et al. Community-acquired septic shock : early management and outcome in a nationwide study in Finland. Acta Anaesthesiol Scand. 51, 2007, 1320-6.
 
14) Yaegashi, Y. et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 11, 2005, 234-8.
PubMed
15) Shozushima, T. et al. Evaluations of PRESEPSIN by a Point-of-Care Test (POC Test) Closely Reflect the Efficacy of Polymyxin-B Immobilized Fiber-Direct Hemoperfusion (PMX-DHP) : A Case Report. J Iwate Med Assoc. 62, 2010, 411-6.
 
16) Shozushima, T. et al. Usefulness of Presepsin (sCD14-ST) Measurements as a Marker for the Diagnosis and Severity of Sepsis in Systemic Inflammatory Response Syndrome. J Infect Chemother. 2011 (in press).
 
17) Takahashi, G. et al. Preliminary study on glucose control with an artificial pancreas in postoperative sepsis patients. Eur Surg Res. 47, 2011, 32-8.
 
18) DuPont, HL. et al. Infections due to gram-negative organisms : an anallysis of 860 patients with bacteremia at the university of Minnesota Medical Center, 1958-1966. Medicine. 48, 1966, 307-30.
 
19) Kreger, BE. et al. Gram-negative bacteremia. Am J Med. 68, 1980, 332-43.
PubMed
20) Setia, U. et al. Bacteremia in a community hospital. Spectrum and mortality. Arch Intern Med. 137, 1977, 1698-701.
 
21) Bryan, CS. et al. Analysis of 12186 episodes of Gram-negative bacteremia in non-university hospitals : The effects of antimicrobial therapy. Rev Infect Dis. 5, 1983, 629-38.
 
22) Uzum, O. et al. Factors influencing prognosis in bacteremia due to Gram-negative organisinsms : evaluation of 448 episodes in a Turkish University Hospital. Clin Infect Dis. 15, 1992, 866-73.
 
23) Roberts, FJ. et al. A three-year study of positive blood cultures, with emphasis on prognosis. Rev Infect Dis. 13, 1991, 34-46.
PubMed
24) Ziegler, EJ. et al. Treatment of Gram-negative bacteremia and septic shock against endotoxin. N Engl J Med. 324, 1991, 429-36.
PubMed
25) Veterans Administration Systemic Sepsis Cooperative Study group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 317, 1987, 659-65.
 
26) Hug, JB. et al. Bloodstream infections at a Norwegian university hospital, 1974-1979 and 1988-1989 : changing etiology, clinical features, and outcome. Clin Infect Dis. 19, 1994, 246-56.
 
27) Pittet, D. et al. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med. 155, 1995, 1177-84.
PubMed
28) Geerdes, HF. et al. Septicemia in 980 patients at a university hospital in Berlin : prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis. 15, 1992, 991-1002.
 
29) Beale, R. et al. Promoting global research excellence in severe sepsis (PROGRESS) : Lessons from an international sepsis registry. Infection. 37, 2009, 222-32.
PubMed
30) 松田直之ほか. Sepsis Registry委員会からの敗血症治療成績の中間報告. 日本集中治療医学会誌. 16, 2009, 207.
 
31) 遠藤重厚ほか. 岩手県高度救命救急センターにおける敗血症治療成績の変遷. エンドトキシン血症救命治療研究会誌. 15, 2011, 16-9.
 

[6] 災害拠点病院である大学病院としての災害時における医療展開とそのコンセプト

P.86 掲載の参考文献
1) 久志本成樹. 東日本大震災における県を支える唯一の大学病院としての医療展開とそのコンセプト. 日救急医会誌. 23, 2012, 231.
 
2) 中川敦寛ほか. 東日本大震災発災後72時間の東北大学病院 : クロノロジー解析から学ぶもの. 日本神経救急医学会雑誌J Jpn Congress Neurol Emerg. 24, 2012, 24-31.
 
3) Nakagawa, A. et al. Chronological analysis in Tohoku University Hospital during the first 72 hours after the Great East Japan Earthquake. IEEE PULSE. 2012 (in press).
 
4) 中川敦寛ほか. 東日本大震災発災直後の神経救急 : 東北大学病院クロノロジーからの考察. 分子脳血管病. 11 (2), 2012, 108-14.
 
5) 古川宗ほか. 病院における震災直後から情報通信の復旧まで : ヒトとモノの流れ. 電子情報通信学会プロシーディング. 2012 (in press).
 
6) 北村聖ほか. 座談会 震災は医療に何をもたらしたか. 災害医療とIT Voice. 2012, 32-45.
 
7) Nakagawa, A. et al. How to continue functioning as Disaster Base Hospitals? Lessons from Great East Japan Earthquake and implications toward future preparedness. Proceedings of APRU. 2012 (in press).
 
8) 久志本成樹ほか. 被災地大学病院として成すべきことは何か?. 日救急医会誌. 2012 (in press).
 
9) 久志本成樹. 津波. 最新医学. 67, 2012, 544-55.
Medical*Online

書評

最近チェックした商品履歴

Loading...